Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

MItochondrial Myopathies: early-phase trial registry

3 of 5 indexed MItochondrial Myopathies trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

MItochondrial Myopathies: 5 US clinical trials tracked, 3 recruiting.

MItochondrial Myopathies is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital of Philadelphia, running 4 of these trials.

Enrollment posture brief

Registry condition mitochondrial-myopathies

OPEN 3 | RECR 60% | LATE 0 | EARLY 5 | RANK #3391 | SPON 4

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%MItochondrial Myopathies (th…60%
Open-enrollment share among volume-matched conditions near MItochondrial Myopathies

MItochondrial Myopathies lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for MItochondrial Myopathies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. MItochondrial Myopathies is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates MItochondrial Myopathies research.

    Children's Hospital of Philadelphia accounts for 4 of 5 trials (80%). 2 distinct sponsors appear on at least one study for this condition label.

  3. Most MItochondrial Myopathies trials plan to enrol fewer than 100 people.

    Median target enrolment is 53 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.

  4. MItochondrial Myopathies research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 21

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on MItochondrial Myopathies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Nanosensor Device
2 trials
Clinical-focused narrative (CFN) Behavioral
1 trials
Promoting Resilience in Stress Management (PRISM) Behavioral
1 trials
omaveloxolone capsules, 20 mg Drug
1 trials
omaveloxolone capsules, 10 mg Drug
1 trials
omaveloxolone capsules, 5 mg Drug
1 trials
Omaveloxolone capsules, 2.5 mg Drug
1 trials
Lumason® contrast agent Drug
1 trials

US sites by state

Facility locations filed on MItochondrial Myopathies trials. A trial with sites in several states counts in each.

Pennsylvania 5 trials
Texas 1 trials
Ohio 1 trials
Massachusetts 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this MItochondrial Myopathies page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MItochondrial Myopathies condition card totals 5 registered trials; most-linked intervention Nanosensor; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.